Merrimack Pharmaceuticals (MACK) Files $172.5M IPO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts MACK Hot Sheet
Join SI Premium – FREE
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) filed a registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. The proposed maximum offering amount is $172.5 million. Merrimack plans to list on the Nasdaq Global Market under the ticker "MACK."
The offering is being made through J.P. Morgan, BofA Merrill Lynch, Cowen and Company, and Oppenheimer & Co.
Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer.
The offering is being made through J.P. Morgan, BofA Merrill Lynch, Cowen and Company, and Oppenheimer & Co.
Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BranchOut Food launches proposed public stock offering
- Rivian acquires Third Dimension AI to boost autonomous driving
- Ping An Biomedical plans to acquire three oncology patents for up to $2.5M
Create E-mail Alert Related Categories
IPOsRelated Entities
JPMorgan, Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
